Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes

Journal of the Pakistan Medical Association

Volumn 60, Issue 11, 2010, Pages 1-5

  Mahmood, Nosheen ^a   Junejo, Abdul Manan ^b   Jamal, Qamar ^a   Awan, Rashid ^c  

^a ZIAUDDIN UNIVERSITY   (Pakistan)

^b Jinnah Postgraduate Medical Centre   (Pakistan)

^c Farman Medical Centre   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; KIDNEY PARENCHYMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; PROTEINURIA; RISK FACTOR;

EID: 78149252469     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-47.
2. Serum Creatinine as Marker of Kidney Function in South Asians: A Study of Reduced GFR in Adults in Pakistan. J Am Soc Nephrol 2005; 16: 1413-1419.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in United States, 2007.
4. Ansell D, Feehally J, Feest TG, Tomson C, Williams AJ, Warwick G. The Renal Association UK Renal Registry.The Tenth Annual Report December 2007.
5. Causes of Chronic Renal Failure in Pakistan: A Single Large Center Experience. Saudi Journal of Kidney Diseases and Transplantation 2002; 13: 376-9.
6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
7. Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O. Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695-702.
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
9. Root AW. Visfatin a new visceral fat adipokine. Growth, Genetics and Hormones 2005; 21: 21-4.
10. Revollo JR, Grimm AA, Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 2007; 23: 164-70.
11. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15: 1851-62.
12. Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-44.
13. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-65.
14. Nüsken KD, Petrasch M, Rauh M, Stöhr W, Nüsken E, Schneider H, et al. Active visfatin is elevated in serum of maintenance haemodialysis patients and correlates inversely with circulating HDL cholesterol. Nephrol Dial Transplant 2009; 24: 2832-8.
15. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin, a new adipocytokine, is predominantly related to inflammation/endothelial damage in kidney allograft recipients. Transplant Proc 2009; 41: 150-3.
16. Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant 2008; 23: 1621-7.
17. Song HK, Lee MH, Kim BK, Park YG, Ko GJ, Kang YS, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: 1485-94.
18. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1-246.
19. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007; 30: 4-41.
20. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
21. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis of abdominal obesity are not applicable uniformly to all populations and ethnic groups. Nutrition 2005; 21: 969-76.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
23. Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor 2003; 544: 74-8.
24. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical endocrinology 2007; 67: 796-800.
25. Stenvinkel P. Inflammation in end-stage renal disease--a fire that burns within. Contrib Nephrol 2005; 149: 185-99.
26. Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009; 23: 241-8.